Phase 2 Eczema Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 12 to under 18 years old, of any gender, who weigh at least 30 kg (about 66 pounds)
• People who have been diagnosed with atopic dermatitis (AD) that meets a recognised set of medical standards, and who have had AD or eczema for at least 6 months before the screening visit
• People whose skin condition scores are at a certain level of severity — specifically, scores on three standard skin assessments (EASI, IGA, and body surface area affected) must meet minimum thresholds at both the screening and baseline visits (confirm exact score thresholds with trial site)
• People whose AD was found to be not well controlled by topical (applied to skin) treatments within the 6 months before screening, or for whom topical treatments are medically unsuitable due to significant side effects, safety risks, allergic reactions, skin thinning, or other treatment reactions
• People who are able to become pregnant or father a child must agree to use effective contraception throughout the study and for 6 months after the last dose
• The participant and/or their parent or legal guardian must be willing to sign a consent form and be able to communicate with the study team and attend follow-up visits as required

Who may not be able to join:

• People who have had a severe allergic reaction to the study drug or similar medications, or who cannot receive injections under the skin (for example, due to blood-thinning medication use, known bleeding disorders, or a condition affecting blood platelets)
• People who have another active skin condition, such as psoriasis or lupus affecting the skin, that could interfere with assessing the eczema
• People who have a disease that may require ongoing treatment with steroid tablets or immune-suppressing medications
• People with certain eye conditions that the study doctor considers unsuitable for participation, such as a history of a serious inflammatory eye condition involving the cornea
• People who have used certain medications within a set period before joining the study, including targeted inhibitors (such as JAK inhibitors), steroid tablets, cyclosporine, other immune-suppressing drugs, PDE4 inhibitors, UV light therapy, systemic herbal treatments for AD, or biologic medicines
• People who have used allergen immunotherapy (allergy desensitisation treatment) in the 6 months before joining the study
• People who have not stopped all topical skin treatments for at least 2 weeks before joining the study
• People who have recently taken part in another clinical trial involving a biologic medicine or a non-biologic medicine within certain timeframes before the study, or who plan to join another drug trial during this study
• People who have previously taken part in a clinical study of this specific product, or who have used a medication that works on a specific immune receptor (IL-4Rα) and, in the study doctor's judgement, developed resistance to it or had serious side effects from it
• People who have received a live or live-attenuated vaccine within 3 months before screening, or who plan to receive one during the study
• People who have had a chronic ongoing infection or a recent serious infection requiring oral or intravenous antibiotics, antiviral, or antifungal treatment within 4 weeks before joining
• People with signs of active tuberculosis or a past history of tuberculosis that was not properly treated
• People who have had a parasitic infection in the 6 months before screening
• People with a history of cancer (malignant tumours)
• People with other serious health conditions — such as heart, metabolic, or neurological diseases — that the study doctor considers unsuitable for immune-suppressing treatment
• People with a history of alcohol or drug misuse in the 6 months before screening
• People who, in the study doctor's opinion, have any other reason that makes participation in the study unsuitable

Important: Always verify eligibility with the trial site directly before applying.